{"nctId":"NCT04556552","briefTitle":"Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders","startDateStruct":{"date":"2020-11-13","type":"ACTUAL"},"conditions":["Substance-Related Disorders","Substance Use Disorders","Substance Abuse, Intravenous","Substance Withdrawal","Substance Abuse","Opioid-use Disorder","Opioid Use Disorder, Severe","Opioid Use"],"count":20,"armGroups":[{"label":"Active non-invasive Vagal nerve stimulation (VNS)","type":"EXPERIMENTAL","interventionNames":["Device: Non invasive VN stimulation (nVNS)","Drug: Oxygen (15-O) Water"]},{"label":"Sham stimulation","type":"SHAM_COMPARATOR","interventionNames":["Drug: Oxygen (15-O) Water","Device: Sham Stimulation"]}],"interventions":[{"name":"Non invasive VN stimulation (nVNS)","otherNames":[]},{"name":"Oxygen (15-O) Water","otherNames":["radiolabelled water"]},{"name":"Sham Stimulation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inclusion Criteria:\n\nSubjects aged 18 and over who meet criteria for OUDs based on the Structured Clinical Interview for DSM-5 (SCID) interview and are stable on medication treatment.\n\nExclusion Criteria:\n\n1. Positive pregnancy test\n2. Meningitis\n3. Traumatic brain injury\n4. Neurological disorder or organic mental disorder\n5. History of loss of consciousness greater than one minute\n6. Current pregnancy or breastfeeding for women\n7. Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID\n8. A history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness\n9. Evidence of a major medical or neurological illness that is based on the clinical judgment of the study psychiatrist\n10. Active implantable device (i.e. pacemaker)\n11. Carotid atherosclerosis\n12. Cervical vagotomy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Opioid Craving Using Visual Analogue Scale","description":"Opioid craving will be measured based on Visual Analogue Scale (VAS) VAS consist in 10-point lines anchored with \"not at all\" on one end and \"extremely\" on the other where participants report the extent to which they felt any craving for opiates, severity of withdrawal symptoms, and the extent to which the study intervention has helped to ease the cravings. Total possible score ranges from 0 to100, with 100 correlating with worse study outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.909","spread":"3.048"},{"groupId":"OG001","value":"6","spread":"2.160"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.556","spread":"2.186"},{"groupId":"OG001","value":"5.5","spread":"3.937"}]}]}]},{"type":"PRIMARY","title":"Heart Rate (HR)","description":"Heart rate will be measured after cue. Decreased HR correlates with better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.357","spread":"8.275"},{"groupId":"OG001","value":"61.575","spread":"10.715"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.192","spread":"9.960"},{"groupId":"OG001","value":"59.003","spread":"10.182"}]}]}]},{"type":"PRIMARY","title":"Pre-ejection Period (PEP)","description":"Pre-ejection Period (PEP) is a marker of cardiac sympathetic tone that is increased with blocked sympathetic function. Higher PEP correlates with better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.048","spread":"0.033"},{"groupId":"OG001","value":"0.069","spread":"0.035"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.050","spread":"0.0320"},{"groupId":"OG001","value":"0.066","spread":"0.0312"}]}]}]},{"type":"PRIMARY","title":"Photoplethysmography (PPG) Amplitude","description":"Photoplethysmography (PPG) amplitude reflects vasoconstriction in figure blood vessel. PPG amplitude is increased with blocked sympathetic tone and higher PPG correlates with better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.411","spread":"1.285"},{"groupId":"OG001","value":"1.684","spread":"0.838"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.162","spread":"2.312"},{"groupId":"OG001","value":"1.459","spread":"0.873"}]}]}]},{"type":"PRIMARY","title":"Brain Blood Flow in the Anterior Cingulate With VNS Paired With Opioid Use Videos","description":"Brain blood flow measured with Positron Emission Tomography (PET) and radiolabeled water at baseline and 2 min post-intervention during viewing of neutral videos and with active and Sham VNS stimulation paired with opioid use videos. Brain blood flow was measured in mL per 100 g of tissue per minute (mL/100g/min) normalized to a reference of 50 ml/100 g of tissue per minute.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":"40.7"},{"groupId":"OG001","value":"44.5","spread":"18.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":"10.2"},{"groupId":"OG001","value":"29.2","spread":"12.2"}]}]}]},{"type":"SECONDARY","title":"Levels of Interleukin 6 (IL-6)","description":"IL-6 is an inflammatory marker. Reduced levels of IL-6 correlate with better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.8"},{"groupId":"OG001","value":"4.0","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"2.6"},{"groupId":"OG001","value":"3.9","spread":"3.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":[]}}}